ATE496905T1 - Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose - Google Patents
Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atheroskleroseInfo
- Publication number
- ATE496905T1 ATE496905T1 AT07810331T AT07810331T ATE496905T1 AT E496905 T1 ATE496905 T1 AT E496905T1 AT 07810331 T AT07810331 T AT 07810331T AT 07810331 T AT07810331 T AT 07810331T AT E496905 T1 ATE496905 T1 AT E496905T1
- Authority
- AT
- Austria
- Prior art keywords
- ccr2
- ccr9
- treatment
- benzenesulfonamides
- triazolyl
- Prior art date
Links
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 title abstract 4
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 title abstract 4
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 title abstract 4
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 title abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 title 1
- 102100036303 C-C chemokine receptor type 9 Human genes 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 102000004900 CC chemokine receptor 9 Human genes 0.000 abstract 1
- 108090001026 CC chemokine receptor 9 Proteins 0.000 abstract 1
- 102000004497 CCR2 Receptors Human genes 0.000 abstract 1
- 108010017312 CCR2 Receptors Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83104206P | 2006-07-14 | 2006-07-14 | |
| US94585407P | 2007-06-22 | 2007-06-22 | |
| PCT/US2007/015786 WO2008008375A2 (en) | 2006-07-14 | 2007-07-10 | Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496905T1 true ATE496905T1 (de) | 2011-02-15 |
Family
ID=38670575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07810331T ATE496905T1 (de) | 2006-07-14 | 2007-07-10 | Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7683176B2 (https=) |
| EP (1) | EP2049515B1 (https=) |
| JP (1) | JP5320291B2 (https=) |
| CN (1) | CN101511800B (https=) |
| AT (1) | ATE496905T1 (https=) |
| AU (1) | AU2007272972B2 (https=) |
| CA (1) | CA2657670C (https=) |
| DE (1) | DE602007012261D1 (https=) |
| ES (2) | ES2358618T3 (https=) |
| WO (1) | WO2008008375A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1748989A2 (en) * | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| US7683176B2 (en) | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| EP2276731A1 (en) * | 2008-04-09 | 2011-01-26 | Boehringer Ingelheim International GmbH | 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10 |
| CN103209960A (zh) * | 2010-07-26 | 2013-07-17 | 百时美施贵宝公司 | 用作cyp17抑制剂的磺酰胺化合物 |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA2852160A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| ES2656012T3 (es) | 2013-02-06 | 2018-02-22 | Bayer Cropscience Aktiengesellschaft | Derivados de pirazol sustituidos con halógeno como pesticidas |
| SG11201600726QA (en) | 2013-07-29 | 2016-03-30 | Merck Patent Gmbh | 1,3-disubstituted cyclopentane derivatives |
| EP3076968B1 (en) * | 2013-12-02 | 2019-04-17 | ChemoCentryx, Inc. | Ccr6 compounds |
| AU2014372638A1 (en) | 2013-12-23 | 2016-06-16 | Norgine B.V. | Compounds useful as CCR9 modulators |
| JP2017503772A (ja) | 2013-12-23 | 2017-02-02 | ノージン ビーブイ | Ｃｃｒ９阻害剤としてのベンゼンスルホンアミド |
| HK1232147A1 (zh) * | 2014-03-21 | 2018-01-05 | Tobira Therapeutics, Inc. | 用於治疗纤维化的赛尼克韦罗 |
| MX2017004344A (es) | 2014-10-06 | 2017-06-07 | Chemocentryx Inc | COMPOSICIONES Y METODOS PARA TRATAR ENFERMEDAD INFLAMATORIA DE INTESTINO USANDO UNA TERAPIA DE COMBINACION DE INHIBIDORES DE MOLECULA PEQUENA DEL RECEPTOR DE QUIMIOCINA C-C TIPO 9 (CCR9) Y ANTICUERPOS BLOQUEADORES ANTI-A4ß7 INTEGRINA. |
| CN104341389A (zh) * | 2014-10-19 | 2015-02-11 | 湖南华腾制药有限公司 | 一种三唑哌啶盐酸盐的制备方法 |
| DK3300500T3 (da) | 2015-05-20 | 2020-05-18 | Amgen Inc | Triazolagonister af apj-receptoren |
| US10000458B2 (en) * | 2016-03-31 | 2018-06-19 | Sumitomo Chemical Company, Limited | Production method of 1, 2, 4-triazole compound |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| SG11201810602YA (en) * | 2016-06-03 | 2018-12-28 | Chemocentryx Inc | Method of treating liver fibrosis |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CN115504986B (zh) | 2017-03-03 | 2024-05-14 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| WO2019016066A1 (de) | 2017-07-18 | 2019-01-24 | Bayer Cropscience Aktiengesellschaft | Substituierte 3-heteroaryloxy-1h-pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| CN114555080B (zh) | 2019-10-16 | 2025-10-10 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的杂芳基联苯胺 |
| AU2020368393B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| TWI904146B (zh) | 2020-03-31 | 2025-11-11 | 美商卡默森屈有限公司 | 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法 |
| CN115477626B (zh) * | 2021-06-16 | 2024-08-02 | 上海璃道医药科技有限公司 | N-取代苯基磺酰胺类化合物及其用途 |
| CN118206536A (zh) * | 2022-12-15 | 2024-06-18 | 上海璃道医药科技有限公司 | N-取代苯基磺酰胺类化合物的固体形式 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0612247A1 (de) | 1991-11-15 | 1994-08-31 | Byk Gulden Lomberg Chemische Fabrik GmbH | Verwendung von sulfonylverbindungen |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| GB2376691B (en) | 2000-06-01 | 2004-06-23 | Nippon Steel Chemical Co | Organic electroluminescent element material and organic electroluminescent element |
| US7227035B2 (en) * | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7420055B2 (en) * | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| US20060111351A1 (en) * | 2002-11-18 | 2006-05-25 | Solomon Ungashe | Aryl sulfonamides |
| US20070021466A1 (en) * | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
| US6939885B2 (en) * | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2005004818A2 (en) | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| JP4322062B2 (ja) * | 2003-07-23 | 2009-08-26 | 日本発條株式会社 | エンジンブロックおよびその製造方法 |
| JP5090730B2 (ja) | 2004-03-03 | 2012-12-05 | 株式会社きもと | 光制御フィルムおよびそれを用いたバックライト装置 |
| EP1748989A2 (en) * | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| ES2440965T3 (es) * | 2005-01-14 | 2014-01-31 | Chemocentryx, Inc. | Heteroaril-sulfonamidas y CCR2 |
| WO2007014054A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| WO2007014008A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| US7683176B2 (en) * | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| MX2009000395A (es) | 2006-07-14 | 2009-01-29 | Chemocentryx Inc | Triazolil fenil bencenosulfonamidas. |
| US7718683B2 (en) * | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US20100234364A1 (en) | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
-
2007
- 2007-07-10 US US11/775,601 patent/US7683176B2/en active Active
- 2007-07-10 ES ES07810331T patent/ES2358618T3/es active Active
- 2007-07-10 EP EP07810331A patent/EP2049515B1/en active Active
- 2007-07-10 CA CA2657670A patent/CA2657670C/en active Active
- 2007-07-10 DE DE602007012261T patent/DE602007012261D1/de active Active
- 2007-07-10 WO PCT/US2007/015786 patent/WO2008008375A2/en not_active Ceased
- 2007-07-10 CN CN200780033360XA patent/CN101511800B/zh active Active
- 2007-07-10 AT AT07810331T patent/ATE496905T1/de not_active IP Right Cessation
- 2007-07-10 ES ES07836049T patent/ES2360741T3/es active Active
- 2007-07-10 JP JP2009520761A patent/JP5320291B2/ja active Active
- 2007-07-10 AU AU2007272972A patent/AU2007272972B2/en active Active
-
2010
- 2010-02-19 US US12/708,900 patent/US8445518B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101511800B (zh) | 2013-02-27 |
| US8445518B2 (en) | 2013-05-21 |
| DE602007012261D1 (de) | 2011-03-10 |
| ES2358618T3 (es) | 2011-05-12 |
| CA2657670A1 (en) | 2008-01-17 |
| HK1131134A1 (en) | 2010-01-15 |
| WO2008008375A3 (en) | 2008-03-06 |
| EP2049515B1 (en) | 2011-01-26 |
| EP2049515A2 (en) | 2009-04-22 |
| ES2360741T3 (es) | 2011-06-08 |
| WO2008008375A2 (en) | 2008-01-17 |
| JP2010504280A (ja) | 2010-02-12 |
| US20100152186A1 (en) | 2010-06-17 |
| CN101511800A (zh) | 2009-08-19 |
| US7683176B2 (en) | 2010-03-23 |
| CA2657670C (en) | 2012-04-17 |
| JP5320291B2 (ja) | 2013-10-23 |
| US20080039504A1 (en) | 2008-02-14 |
| AU2007272972A1 (en) | 2008-01-17 |
| AU2007272972B2 (en) | 2011-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE496905T1 (de) | Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose | |
| DK2046762T3 (da) | Triazolphenylbenzensulfonamider | |
| ATE548039T1 (de) | Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen | |
| WO2008008374A3 (en) | Ccr2 inhibitors and methods of use thereof | |
| MX2007008474A (es) | Sulfonamidas de heteroarilo y ccr2. | |
| ATE438401T1 (de) | 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen | |
| DK1798223T3 (da) | Arylsulfonamider | |
| CA2865714C (en) | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists | |
| EA200901583A1 (ru) | N-(2-(гетарил)арил)арилсульфонамиды и n-(2-(гетарил)гетарил)арилсульфонамиды | |
| EA201070148A1 (ru) | Соединения и способы модулирования фарнезоидного рецептора x (fxr) | |
| ATE465150T1 (de) | Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate | |
| ATE375977T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
| ATE505468T1 (de) | N-gebundene heterocyclische antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
| ATE469173T1 (de) | Pegyliertes pth als pth-rezeptormodulatoren und ihre verwendung | |
| DE602006016413D1 (de) | Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen | |
| DE602005026699D1 (de) | Vorrichtung zur behandlung von hauterkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |